| Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials E Pons-Tostivint, A Latouche, P Vaflard, F Ricci, D Loirat, S Hescot, ... JCO Precision Oncology 3, 1-10, 2019 | 108 | 2019 |
| Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie C Basse, C Morel, M Alt, MP Sablin, C Franck, G Pierron, C Callens, ... ESMO open 3 (3), e000339, 2018 | 49 | 2018 |
| Prospective evaluation of ultrafast breast MRI for predicting pathologic response after neoadjuvant therapies T Ramtohul, C Tescher, P Vaflard, J Cyrta, N Girard, C Malhaire, ... Radiology 305 (3), 565-574, 2022 | 35 | 2022 |
| Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers SI Labidi-Galy, TLM Rouge, O Derbel, A Wolfer, E Kalbacher, T Olivier, ... Gynecologic oncology 155 (2), 262-269, 2019 | 32 | 2019 |
| Dissociated responses in patients with metastatic solid tumors treated with immunotherapy P Vaflard, X Paoletti, V Servois, P Tresca, E Pons-Tostivint, MP Sablin, ... Drugs in R&D 21, 399-406, 2021 | 19 | 2021 |
| Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial J Taïeb, O Bouche, T André, K Le Malicot, P Laurent-Puig, J Bez, ... JAMA oncology 9 (10), 1356-1363, 2023 | 17 | 2023 |
| Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil P Vaflard, S Ederhy, C Torregrosa, T Andre, R Cohen, D Lopez-Trabada Bulletin du cancer 105 (7-8), 707-719, 2018 | 12 | 2018 |
| FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study C Torregrosa, S Pernot, P Vaflard, A Perret, C Tournigand, V Randrian, ... International journal of cancer 151 (11), 1978-1988, 2022 | 9 | 2022 |
| Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centre L Thery, P Vaflard, P Vuagnat, O Soulie, S Dolbeault, A Burnod, ... BMJ supportive & palliative care 14 (e1), e594-e599, 2021 | 9 | 2021 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases A De Moura, D Loirat, S Vaillant, S Korbi, N Kiavue, D Bello Roufai, ... Breast Cancer 31 (4), 572-580, 2024 | 8 | 2024 |
| Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program A de Moura, P Vuagnat, B Renouf, JY Pierga, D Loirat, P Vaflard, ... Scientific Reports 13 (1), 13427, 2023 | 3 | 2023 |
| DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study S Kim, V Vendrely, A Saint, T André, P Vaflard, E Samalin, S Pernot, ... Experimental Hematology & Oncology 12 (1), 63, 2023 | 3 | 2023 |
| Nouvelle AMM européenne: pembrolizumab en association à la chimiothérapie en première ligne des carcinomes épidermoïdes de l’œsophage ou des adénocarcinomes de la jonction … S Quesada, P Vaflard Bulletin du Cancer 109 (2), 111-113, 2022 | 3 | 2022 |
| Première vague COVID-19: Expérience d’un centre de lutte contre le cancer M Frelaut, P Vaflard, P Vuagnat, L Bozec, P Moreau, I Kriegel, D Vanjak, ... Bulletin du Cancer 108 (6), 571-580, 2021 | 3 | 2021 |
| Hyperprogressive disease after pembrolizumab treatment in advanced Epstein-Barr Virus–associated gastric adenocarcinoma with ERBB2 amplification S Watson, J Cyrta, M Lefevre, JM Planchon, C Louvet, V Servois, ... JCO Precision Oncology 5, 370-377, 2021 | 3 | 2021 |
| La toxicité cardiaque des fluoropyrimidines: 5-fluorouracile, capécitabine, le composé S-1 et le trifluridine/tipiracil P Vaflard, S Ederhy, C Torregrosa, T André, R Cohen, D Lopez-Trabada Bulletin du Cancer 105 (7-8), 707-719, 2018 | 3 | 2018 |
| Errors in prescribing injectable anticancer drugs: benefits of a pharmaceutical long-term monitoring to improve patient safety in a European comprehensive cancer centre M Dupre, L Escalup, S Blondeel-Gomes, P Vaflard, R Desmaris, P Cottu, ... European Journal of Hospital Pharmacy, 2023 | 2 | 2023 |
| 216P Sacituzumab govitecan in metastatic triple-negative breast cancer: Efficacy-with a focus on brain metastases-and toxicity in a real-world cohort D Loirat, A De Moura, S Korbi, N Kiavue, L Escalup, R Desmaris, L Cabel, ... ESMO Open 8 (1), 2023 | 2 | 2023 |
| Abstract P3-06-09: Real-world toxicity of pembrolizumab-based neoadjuvant regimen in patients with early triple negative breast cancer D Loirat, E ARNAUD, K ALAOUI, P VAFLARD, S KORBI, D MEZIANI, ... Cancer Research 83 (5_Supplement), P3-06-09-P3-06-09, 2023 | 2 | 2023 |
| New drug approval: pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal … S Quesada, P Vaflard Bulletin Du Cancer 109 (2), 111-113, 2022 | 2 | 2022 |
